Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

Outlook for medicines development and use in 2025

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 24, 73-74 (2025)

doi: https://doi.org/10.1038/d41573-025-00012-2

References

  1. Atri, A. et al. Evoke and Evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer’s disease. Alzheimers Dement. 18, e062415 (2022).

    Article  Google Scholar 

Download references

Competing Interests

The authors of this article are employees of IQVIA, a provider of data and services to the life sciences industry and to healthcare providers that works with the world's leading biopharmaceutical companies. The research for this specific article was funded by IQVIA.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Quick links